| Literature DB >> 30521975 |
Yoshihiro Inamoto1, Igor Petriček2, Linda Burns3, Saurabh Chhabra4, Zachariah DeFilipp5, Peiman Hematti6, Alicia Rovó7, Raquel Schears8, Ami Shah9, Vaibhav Agrawal10, Aisha Ahmed11, Ibrahim Ahmed12, Asim Ali13, Mahmoud Aljurf14, Hassan Alkhateeb8, Amer Beitinjaneh15, Neel Bhatt16, Dave Buchbinder17, Michael Byrne18, Natalie Callander19, Kristina Fahnehjelm20, Nosha Farhadfar21, Robert Peter Gale22, Siddhartha Ganguly23, Shahrukh Hashmi14, Gerhard C Hildebrandt24, Erich Horn21, Ann Jakubowski25, Rammurti T Kamble26, Jason Law27, Catherine Lee28, Sunita Nathan29, Olaf Penack30, Ravi Pingali31, Pinki Prasad32, Drazen Pulanic33, Seth Rotz34, Aditya Shreenivas35, Amir Steinberg35, Khalid Tabbara36, André Tichelli37, Baldeep Wirk38, Jean Yared39, Grzegorz W Basak40, Minoo Battiwalla41, Rafael Duarte42, Bipin N Savani18, Mary E D Flowers43, Bronwen E Shaw16, Nuria Valdés-Sanz44.
Abstract
Non-graft-versus-host disease (GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT) but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. We summarize the incidence, risk factors, screening, prevention, and treatment of individual complications and generate evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical signs and symptoms and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplantation physicians and ophthalmologists should be knowledgeable about non-GVHD ocular complications and provide comprehensive collaborative team care.Entities:
Keywords: Complication; Eye; Hematopoietic cell transplantation; Prevention; Review; Treatment
Mesh:
Year: 2018 PMID: 30521975 PMCID: PMC6511311 DOI: 10.1016/j.bbmt.2018.11.033
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN: 1083-8791 Impact factor: 5.742